QUINCY, Mass. — The National Organization for Rare Disorders (NORD), the leading national nonprofit serving more than 30 million Americans living with rare diseases, has announced the recipients of its latest seed grant funding cycle. Totaling $145,000, these new awards are designed to support innovative, high-impact studies targeting four critically underserved conditions that have historically lacked sufficient research funding, therapeutic options, and standardized clinical guidelines.
The newly funded research projects focus on four distinct and complex medical conditions: appendix cancer/pseudomyxoma peritonei (ACPMP), epidermodysplasia verruciformis (EV), Peutz-Jeghers syndrome (PJS), and partial trisomy 6q. Financial backing for this funding cycle comes from a collaborative effort uniting the ACPMP Research Foundation, which is a NORD Member patient advocacy organization; the pseudomyxoma peritonei, Peutz-Jeghers syndrome, and epidermodysplasia verruciformis communities; Dylan’s Rare Chromosome Dream Team; and the partial trisomy 6q patient community.
This latest funding cycle marks another critical milestone in NORD’s ongoing mission to bridge the immense gap in rare disease research. With fewer than 5% of the approximately 10,000 known rare diseases currently having an FDA-approved therapy, early-stage seed grants are widely recognized by the scientific community as essential catalysts. They provide investigators with the necessary initial funding to explore novel hypotheses, gather preliminary data, and position their studies to attract much larger investments from major institutions, federal agencies such as the National Institutes of Health (NIH) or the U.S. Food and Drug Administration (FDA), and corporate sponsors.
Tracey Sikora, NORD Vice President of Research and Clinical Programs, expressed enthusiasm for the groundbreaking projects selected for this funding cycle and praised the dedication of the researchers involved.
"Huge congratulations to our seed grant recipients — Drs. Sommariva, Ahuja, and Piovani! Their groundbreaking work represents a major leap forward for everyone affected by ACPMP, EV, PJS, and Partial Trisomy 6q," said Sikora. "We’re thrilled to champion innovative research that directly tackles the urgent, unmet needs of rare disease communities. We can’t wait to see how their insights will transform patient care and drive the future of rare disease research."
The grants have been awarded to three distinguished researchers whose studies address significant clinical gaps in understanding pathogenesis, improving diagnostic clarity, and identifying potential new therapeutic targets.
Among the awarded projects is a study led by Dr. Sommariva, titled “Analysis of TROP2 expression in Pseudomyxoma Peritonei (PMP).” Pseudomyxoma peritonei is a rare and challenging condition characterized by the widespread production of gelatinous mucus within the abdominal cavity, typically originating from an epithelial appendiceal neoplasm. Cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy, commonly known as CRS-HIPEC, has been shown to greatly improve both survival rates and the overall quality of life for many patients affected by the disease.
However, a significant portion of patients cannot undergo this intensive surgical procedure
, and systemic chemotherapy options remain severely limited, often consisting essentially of palliative measures. Sommariva’s research focuses on a promising potential therapeutic target known as trophoblast cell surface antigen 2, or TROP2. Specific agents targeting TROP2 have already been developed and approved by the FDA for various other solid tumors, making it a logical candidate for investigation in PMP. Preliminary results have already confirmed the overexpression of TROP2 in PMP tumor cells. The overarching aim of the newly funded study is to expand and strengthen this initial evidence while gaining deeper insights into the precise role TROP2 plays in PMP pathogenesis. Establishing this foundational understanding is a mandatory prerequisite for identifying a new target for combinatory and adjuvant therapies.

Another vital area of investigation receiving NORD funding is led by Dr. Ahuja, who has secured support for two distinct projects utilizing advanced technology to address severe clinical surveillance gaps. Ahuja’s first study is titled “Quantifying Malignancy and Treatment Effectiveness in EV: A Real-World Evidence Study of Surveillance Gaps.” Individuals diagnosed with epidermodysplasia verruciformis (EV) face an exceptionally high lifetime risk of developing aggressive skin cancers. This heightened vulnerability is driven by specific underlying genetic mutations combined with persistent infections caused by human papillomaviruses, or HPV.
Despite the profound health risks faced by these patients, real-world data tracking surveillance routines and treatment outcomes for EV remains severely limited. To overcome this hurdle, Ahuja’s project will utilize advanced, privacy-preserving artificial intelligence to securely extract critical clinical details directly from unstructured dermatopathology reports. These details include specific HPV subtypes, skin cancer recurrence patterns, and the precise physical locations of lesions. By translating this currently hidden medical information into robust real-world evidence, the research team aims to quantify existing surveillance gaps and help establish standardized, evidence-based care guidelines designed to improve malignancy-free survival rates across the entire EV community.
Ahuja’s second funded project investigates Peutz-Jeghers syndrome (PJS) through a study titled “Risk-Stratification of PJS Complications: A RWE Study on STK11 Variant Effects on Emergency Surgery and Cancer Onset.” PJS is a rare hereditary condition that carries a high lifetime risk of severe gastrointestinal complications and aggressive cancers. Currently, routine clinical screening guidelines fail to account for the specific genetic mutations that actively drive the disease progression in individual patients.
To address this deficiency, Ahuja’s project will similarly leverage advanced, privacy-preserving artificial intelligence to securely extract complex genetic data from comprehensive medical records. The research will directly correlate specific STK11 genetic mutations with the precise age of onset for emergency surgeries and malignancies. By translating this real-world data into actionable clinical evidence, the project aims to help establish precision, variant-specific surveillance protocols. These tailored protocols are expected to prevent life-threatening medical emergencies and significantly improve long-term health outcomes for individuals living with PJS.
The fourth seed grant was awarded to Dr. Piovani for a study titled “Partial Trisomy 6q: Clinical Characterization, Genomic Profiling, and Patient-Specific iPSC Models for Functional Disease Investigation.” Partial trisomy 6q is a rare chromosomal disorder characterized by the duplication of a segment of the long arm of chromosome 6. Currently, very little is known about the condition, which makes both accurate diagnosis and effective genetic counseling exceptionally challenging for affected individuals and their grieving or concerned families.
Piovani’s project aims to bridge this knowledge gap by combining detailed clinical information and genomic profiling with patient-derived stem cell models. Specifically, the research will utilize induced pluripotent stem cells, or iPSCs, to investigate how partial trisomy 6q disrupts normal human development and to identify the underlying biological mechanisms driving the disorder. The results of this study are expected to provide invaluable resources for the broader rare disease community and lay a strong scientific groundwork for future research aimed directly at improving patient care and clinical management.
The funding is administered through NORD’s established Rare Disease Research Grant Program, which has a long history of supporting qualified researchers dedicated to advancing scientific discovery. The program is specifically structured to support new or existing scientific research studies and clinical trials that hold the promise of generating preliminary data robust enough to attract larger-scale funding from major federal and private sources.
Since its inception in 1989, NORD has awarded more than $9 million in research grants to advance scientific understanding and therapeutic development for rare diseases that otherwise lack adequate treatment options and financial support. NORD’s grant program has successfully jump-started urgent rare disease research projects, supported numerous peer-reviewed scientific publications, and directly contributed to the development of two FDA-approved treatments.
Founded in 1983, the National Organization for Rare Disorders operates as an independent, nonprofit, nonpartisan organization dedicated to improving the health and lives of the more than 30 million Americans living with rare diseases. NORD achieves its mission in partnership with more than 350 disease-specific member patient organizations and a robust Rare Disease Centers of Excellence network that spans more than 170 medical and research institutions and children’s hospitals across the country. Through these collaborative networks, NORD advances comprehensive care, groundbreaking research, public education, and legislative advocacy on behalf of the entire rare disease community.
